PDUFA VIII commitments: ‘America First’ provisions, faster reviews and morenews2026-08-13T17:55:02+00:00August 13th, 2026|Endpoints News|
Karyopharm has a month left to salvage its cancer expansion plansnews2026-08-13T14:43:15+00:00August 13th, 2026|Endpoints News|
Zealand’s royalty deal; Khartis raises money for TED drugnews2026-08-13T14:19:46+00:00August 13th, 2026|Endpoints News|
Aligned Marketplace raises $20M to match employers with primary carenews2026-08-13T13:00:52+00:00August 13th, 2026|Endpoints News|
Taiho, Cullinan’s lung cancer drug passes Phase 3 test, lining up Rybrevant contestnews2026-08-13T11:11:47+00:00August 13th, 2026|Endpoints News|
PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auctionnews2026-08-13T10:30:26+00:00August 13th, 2026|Endpoints News|
Four questions on new safety warnings for Neurocrine’s Vykat XRnews2026-08-12T18:48:41+00:00August 12th, 2026|Endpoints News|
Vaccine makers throw cold water on separating MMR vaccinenews2026-08-12T18:17:06+00:00August 12th, 2026|Endpoints News|
GDUFA IV commitments: New onshoring incentives and meeting types for generic drugsnews2026-08-12T17:26:54+00:00August 12th, 2026|Endpoints News|
Eli Lilly files first lawsuits over retatrutide ‘black market’news2026-08-12T16:38:05+00:00August 12th, 2026|Endpoints News|
